Learn More
Bisphosphonates (BPs) and denosumab reduce the risk of spine and nonspine fractures. Atypical femur fractures (AFFs) located in the subtrochanteric region and diaphysis of the femur have been reported in patients taking BPs and in patients on denosumab, but they also occur in patients with no exposure to these drugs. In this report, we review studies on the(More)
Reports linking long-term use of bisphosphonates (BPs) with atypical fractures of the femur led the leadership of the American Society for Bone and Mineral Research (ASBMR) to appoint a task force to address key questions related to this problem. A multidisciplinary expert group reviewed pertinent published reports concerning atypical femur fractures, as(More)
Areal bone mineral density (aBMD) is used in clinical practice to diagnose osteoporosis. In previous studies, aBMD was estimated from diagnostic computed tomography (dCT) images, but a battery of medical tests was also taken that can be used to improve the regression performance. However, it is difficult to exploit the multimodal data as the additional(More)
Patients with monoclonal gammopathy of undetermined significance (MGUS) are at increased fracture risk, and we have previously shown that MGUS patients have altered trabecular bone microarchitecture compared with controls. However, there are no data on whether the porosity of cortical bone, which may play a greater role in bone strength and the occurrence(More)
  • Elizabeth Shane Co-Chair, David Burr Co-Chair, +26 authors David Burr
  • 2010
The American Society for Bone and Mineral Research (ASBMR) is well served by the fact that many of those responsible for policy development and implementation have diverse interests and are involved in a variety of activities outside of the Society. The ASBMR protects itself and its reputation by ensuring impartial decision-making. disclose any real or(More)
  • 1